Abstract
Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.
| Original language | English (US) |
|---|---|
| Journal | Transplantation Proceedings |
| Volume | 36 |
| Issue number | 2 SUPPL. |
| DOIs | |
| State | Published - Mar 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Transplantation
Cite this
Pharmacology of calcineurin antagonists. / Kapturczak, M. H.; Meier-Kriesche, H. U.; Kaplan, B.
In: Transplantation Proceedings, Vol. 36, No. 2 SUPPL., 03.2004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacology of calcineurin antagonists
AU - Kapturczak, M. H.
AU - Meier-Kriesche, H. U.
AU - Kaplan, B.
PY - 2004/3
Y1 - 2004/3
N2 - Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.
AB - Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.
UR - http://www.scopus.com/inward/record.url?scp=1642317043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642317043&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2004.01.018
DO - 10.1016/j.transproceed.2004.01.018
M3 - Article
C2 - 15041303
AN - SCOPUS:1642317043
VL - 36
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 2 SUPPL.
ER -